JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Barosi, Giovanni ^a   Poletto, Valentina ^a   Massa, Margherita ^a   Campanelli, Rita ^a   Villani, Laura ^a   Bonetti, Elisa ^a   Viarengo, Gianluca ^a   Catarsi, Paolo ^a   Klersy, Catherine ^a   Rosti, Vittorio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST TRANSFORMATION; CHILD; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; JANUS KINASE 2 GENE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID METAPLASIA; OVERALL SURVIVAL; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; VALIDATION PROCESS; WILD TYPE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; BONE MARROW CELLS; CHILD; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875474755     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059791     Document Type: Article

References (37)

1. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, et al. (2012) One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 87: 25-33.
2. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, et al. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110: 4030-4036.
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, et al. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895-2901.
4. Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, et al. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107: 2098-2100.
5. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, et al. (2005) The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131: 320-328.
6. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, et al. (2010) Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood115: 2882-2890.
7. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, et al. (2006) JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 30: 1457-1460.
8. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, et al. (2008) The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 112: 1628-1637.
9. Lopes da Silva R, Ribeiro P, Lourenço A, Santos SC, Santos M, et al. (2011) What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms? Lab Hematol 17: 12-16.
10. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, et al. (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22: 756-761.
11. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, et al. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114: 1477-1483.
12. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, et al. (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118: 5227-5234.
13. Andersen PK, Geskus RB, de Witte T, Putter H, (2012) Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 41: 861-870.
14. Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, et al. (2012) Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. PLoS One 7(4): e35631.
15. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A, (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 8: 1128-1132.
16. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
17. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, et al. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106: 1207-1209.
18. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, et al. (2006) The JAK2-V617F mutation is frequently presentat diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108: 1865-1867.
19. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, et al. (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31: 737-740.
20. Fine J P, Gray R J, (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509.
21. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, et al. (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24: 1574-1579.
22. Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, et al. (2011) Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol 86: 974-979.
23. Anand S, Stedham F, Beer P, Gudgin E, Ortmann CA, et al. (2011) Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 118: 177-181.
24. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, et al. (2008) JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112: 1402-1412.
25. Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJ, et al. (2008) Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med 359: 2778-2789.
26. Dawson MA, Bannister AJ, Göttgens B, Foster SD, Bartke T, et al. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819-822.
27. Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, et al. (2012) JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 31: 1323-1333.
28. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, et al. (2007) Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110: 375-379.
29. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, et al. (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108: 3548-3555.
30. Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, et al. (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115: 2891-2900.
31. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, et al. (2011) Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 25: 1834-1839.
32. Ricci C, Spinelli O, Salmoiraghi S, Finazzi G, Carobbio A, et al. (2012) ASXL1 mutations in primary and secondary myelofibrosis. Br J Haematol 156: 404-407.
33. Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, et al. (2012) Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative/myelodysplastic disorders: an analysis of 636 cases. Haematologica Jun 24[Epub ahead of print].
34. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, et al. (2010) LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 24: 1713-1718.
35. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, et al. (2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24: 1302-1309.
36. Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, et al. (2012) Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia Jan 13[Epub ahead of print].
37. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798.